Contrasting Cerus (NASDAQ:CERS) and Evolus (NASDAQ:EOLS)

Cerus (NASDAQ:CERS) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

78.4% of Cerus shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 5.6% of Cerus shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Cerus and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
Evolus	-14.39%	N/A	-19.03%

Analyst Ratings

This is a summary of current ratings and price targets for Cerus and Evolus, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1	1	2	0	2.25
Evolus	1	1	4	0	2.50

Cerus presently has a consensus target price of $4.00, indicating a potential upside of 31.58%. Evolus has a consensus target price of $16.00, indicating a potential upside of 143.90%. Given Evolus’ stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Cerus.

Volatility & Risk

Cerus has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cerus and Evolus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$216.56 million	2.81	-$15.63 million	($0.05)	-60.80
Evolus	$297.18 million	1.45	-$51.64 million	($0.67)	-9.79

Cerus has higher earnings, but lower revenue than Evolus. Cerus is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.